Novartis’ Lutathera, a drug indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, including foregut, midgut, and hindgut tumors, was recently highlighted at the World Congress on Gastrointestinal Cancer 2021. Dr. Jonathan R. Strosberg, head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Fla., presented positive survival data from the Phase 3 NETTER-1 trial.
The study demonstrated that Lutathera significantly improved survival outcomes in patients with midgut neuroendocrine tumors. Specifically, the drug extended survival by 11.7 months compared to the control group. These findings underscore the potential of Lutathera as an effective treatment option for patients with this type of cancer.
Filed Under: Oncology